Clinical Trials
6 trialsNCT05458180 2022-07-14
CMOEP in the Treatment of Untreated Peripheral T-cell Lymphoma
Tianjin Medical University Cancer Institute and Hospital
Phase 1 Unknown
NCT04108325 2021-01-28
A Phase Ib Study of YY-20394 in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma
Shanghai YingLi Pharmaceutical Co. Ltd.
Phase 1 Unknown
NCT04480788 2021-01-06
CD7-CART in the Treatment of r / r CD7 Positive Hemolymph System Malignancies on Increasing Dose and Open Label Study
PersonGen BioTherapeutics (Suzhou) Co., Ltd.
Phase 1 Unknown
NCT03921879 2020-10-23
Safety and Efficacy of OT-82 in Participants With Relapsed or Refractory Lymphoma
Oncotartis, Inc.
Phase 1 Unknown
NCT04008394 2019-08-07
Anti-CD30 CAR-T Therapy in Patients With Refractory/Relapsed Lymphocyte Malignancies
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Phase 1 Unknown
NCT00562068 2013-08-26
Alemtuzumab and Combination Chemotherapy in Treating Patients With Stage I, Stage II, Stage III, or Stage IV Peripheral T-Cell Lymphoma
National Cancer Institute (NCI)
Phase 1 Unknown